BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T083000
DTEND;TZID=America/New_York:20260517T093000
DTSTAMP:20260513T141843
CREATED:20260421T145042Z
LAST-MODIFIED:20260507T133522Z
UID:10001725-1779006600-1779010200@lifescievents.com
SUMMARY:UroGen Pharma - Right Patient\, Right Treatment: Real-World Insights on ZUSDURI™(mitomycin) for Intravesical Solution
DESCRIPTION:Join UroGen Pharma for a virtual investor event featuring key opinion leaders (KOLs) Karim Chamie\, MD (UCLA Health)\, Aaron Berger\, MD (Associated Urological Specialists\, Chicago)\, and Jennifer Linehan\, MD (Saint John’s Cancer Institute at Providence\, Santa Monica)\, who will join UroGen management to discuss the significant unmet need and current treatment landscape for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). \nThe event will include an overview of UroGen’s ZUSDURI™\, the first and only FDA-approved medicine for adults with recurrent LG-IR-NMIBC. The KOL panel will share real-world clinical perspectives on the use of ZUSDURI\, including patient selection\, integration into practice\, and observed outcomes. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/kfw04gs3/.
URL:https://lifescievents.com/event/kfw04gs3/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/UroGen-Banner-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T110000
DTEND;TZID=America/New_York:20260518T123000
DTSTAMP:20260513T141843
CREATED:20260415T171240Z
LAST-MODIFIED:20260429T165506Z
UID:10001722-1779102000-1779107400@lifescievents.com
SUMMARY:Rapid Medical Virtual KOL Event Featuring DISTALS Clinical Trial Results: First Positive Data in MeVO Distal Ischemic Stroke Segment\, Featuring TIGERTRIEVER™ 13
DESCRIPTION:Join Rapid Medical for a virtual key opinion leader (KOL) event featuring Ronen Eckhouse\, Co-Founder & CEO of Rapid Medical\, alongside leading stroke experts Jeffrey Saver\, MD (UCLA) and Shahram Majidi\, MD (Mount Sinai)\, who will provide clinical perspectives on the evolving treatment paradigm in ischemic stroke. \nThe discussion will provide clinical perspectives on a major advancement in ischemic stroke treatment\, including an overview of the new data from Rapid Medical’s DISTALS study evaluating the TIGERTRIEVER™ 13 platform. The first positive clinical results in the emerging medium vessel occlusion (MeVO) segment— featuring DISTALS study data on the TIGERTRIEVER™ 13. \nTIGERTRIEVER™ is the only active thrombectomy device\, engineered to adapt to patient anatomy\, accelerate clot integration\, and reduce stress on the brain during mechanical thrombectomy procedures. The DISTALS study represents the first randomized evidence demonstrating superiority of a device-based intervention over medical management in distal stroke\, potentially expanding the treatable patient population and reshaping clinical practice. Management will also discuss implications for future treatment protocols and market expansion. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/yw09tkp5/.
URL:https://lifescievents.com/event/yw09tkp5/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Rapid-Medical-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260527T080000
DTEND;TZID=America/New_York:20260527T093000
DTSTAMP:20260513T141843
CREATED:20260415T164745Z
LAST-MODIFIED:20260430T151349Z
UID:10001719-1779868800-1779874200@lifescievents.com
SUMMARY:BioInvent Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer
DESCRIPTION:Join BioInvent for a virtual key opinion leader (KOL) event featuring Dmitriy Zamarin MD\, PhD (Tisch Cancer Center\, Icahn School of Medicine at Mount Sinai)\, who will join company management to discuss the unmet need and current treatment landscape for ovarian cancer. \nThe event will provide an overview of BI-1808\, a first-in-class drug candidate which has shown clinical proof-of-concept (single agent as well as in combination with pembrolizumab) in clinical Phase 2 development for the treatment of ovarian cancer. The interim data from 21 evaluable patients who received BI-1808 plus pembrolizumab showed three times the overall response rate (ORR) of pembrolizumab alone in heavily pretreated ovarian cancer patients. Management will also discuss the competitive differentiation as well as upcoming data milestones. This event is the first in a two-part KOL series. A second event taking place on June 11th will focus on BI-1206 and BI-1808 for the treatment of non-Hodgkin’s lymphoma and cutaneous T-cell lymphoma\, respectively. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/ogme0jt7/.
URL:https://lifescievents.com/event/ogme0jt7/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/BioInvent-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260601T063000
DTEND;TZID=America/Chicago:20260601T073000
DTSTAMP:20260513T141843
CREATED:20260409T135333Z
LAST-MODIFIED:20260423T141613Z
UID:10001715-1780295400-1780299000@lifescievents.com
SUMMARY:Corbus Pharmaceuticals - In-Person and Virtual Investor Event to Discuss Updated CRB–701 Monotherapy Data in HNSCC
DESCRIPTION:Join Corbus Pharmaceuticals for an in-person and virtual investor event featuring key opinion leaders (KOLs) Ari Rosenberg\, MD (UChicago Medicine)\, Glenn Hanna\, MD (Dana-Farber Cancer Institute)\, and Cesar Augusto Perez Batista\, MD (Sarah Cannon Research Institute)\, hosted by Yuval Cohen\, Corbus CEO to discuss updated data from its Phase 1/2 clinical study of CRB-701 in over 75 participants with head and neck squamous cell carcinoma (HNSCC). Data will include clinical response durability as well as HNSCC patient subgroup analysis. These data will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026\, to be held May 29 – June 2\, 2026 in Chicago\, IL. \nThe ongoing three-part Phase 1/2 study has evaluated the safety\, pharmacokinetics and efficacy of CRB-701 in over 317 participants with advanced solid tumors associated with high Nectin-4 expression. CRB-701 is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4\, that contains a site-specific\, cleavable linker and a homogenous drug antibody ratio of 2\, using MMAE as the payload. \nCorbus recently announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC. \nA live question and answer session will follow the formal presentation and discussion. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/rk0t83lp/.
URL:https://lifescievents.com/event/rk0t83lp/
LOCATION:Marriott Marquis Chicago & Live Webcast\, Marriott Marquis Chicago\, 2121 S Prairie Ave\, Chicago\, IL 60616
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Corbus-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260606T070000
DTEND;TZID=America/Chicago:20260606T090000
DTSTAMP:20260513T141843
CREATED:20260415T185227Z
LAST-MODIFIED:20260504T211952Z
UID:10001723-1780729200-1780736400@lifescievents.com
SUMMARY:Senseonics In-Person & Virtual Analyst Event
DESCRIPTION:Please join Senseonics for an in-person and virtual Analyst Event in New Orleans. \nSenseonics management will provide a comprehensive update on Eversense 365 commercial progress\, including European launch\, integration with the Sequel twiist pump\, pipeline development activities (including the Gemini and Freedom programs)\, and clinical data being presented at ADA. \nA live analyst question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/lj194bw/.
URL:https://lifescievents.com/event/lj194bw/
LOCATION:New Orleans Marriott Warehouse District\, 859 Convention Center Blvd\, New Orleans\, Louisiana\, 70130
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Senseonics-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260617T140000
DTEND;TZID=America/New_York:20260617T160000
DTSTAMP:20260513T141843
CREATED:20260330T170509Z
LAST-MODIFIED:20260505T132414Z
UID:10001710-1781704800-1781712000@lifescievents.com
SUMMARY:Ocular Therapeutix™ Investor Day 2026
DESCRIPTION:Please join Ocular Therapeutix™ for its 2026 Investor Day. The Event will feature prominent retinal disease Key Opinion Leaders (KOLs) and presentations from senior Company leadership. \nKey areas of focus include:\n• Regulatory updates regarding NDA submission plan for AXPAXLI™ in wet AMD\n• Detailed updates on SOL-R and SOL-X\n• Registrational program update in diabetic retinopathy\n• Overview of the planned commercialization strategy for AXPAXLI\, if approved \nA live question and answer session and cocktail reception will follow the formal presentations. Additional event information and logistics will be provided in advance. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sw02gl7/.
URL:https://lifescievents.com/event/sw02gl7/
LOCATION:Midtown\, New York and Live Webcast\, Midtown\, New York and Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/03/Ocular-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260625T090000
DTEND;TZID=America/New_York:20260625T120000
DTSTAMP:20260513T141843
CREATED:20260421T152009Z
LAST-MODIFIED:20260511T162023Z
UID:10001726-1782378000-1782388800@lifescievents.com
SUMMARY:Hansa Biopharma Capital Markets Day
DESCRIPTION:Join Hansa Biopharma for a Capital Markets Day featuring key opinion leaders: Matthew Cooper\, MD (Medical College of Wisconsin)\, Nassim Kamar\, MD\, PhD (Toulouse University Hospital\, France)\, Roslyn Mannon\, MD (University of Nebraska Medical Center)\, and Annette Jackson\, PhD\, F(ACHI) (Duke University Medical Center)\, and presentations by management on the Company’s pre-launch activities and pipeline strategy. \nThe program will include a review of the results from the pivotal U.S. Phase 3 ConfIdeS study presented at ATC on June 20-24\, 2026\, as well as findings from the European Post‑Authorisation Efficacy and Safety (PAES) study with Idefirix/imlifidase in Europe. Discussions with KOLs will focus on the medical need in the context of existing alternatives today for highly sensitized patients\, as well as experiences from the Phase 3 study. Company presentations will address the market opportunity and Hansa Biopharma’s pre-launch and commercialization preparations ahead of a potential U.S. approval. The day will also feature an update on Hansa’s development program for the next generation enzyme HNSA-5487 in Guillain-Barré syndrome. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sl49bte8/.
URL:https://lifescievents.com/event/sl49bte8/
LOCATION:St. Regis Hotel\, New York\, St. Regis Hotel\, New York & Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Banners-3-2.png
END:VEVENT
END:VCALENDAR